** Shares of Chinese pharmaceutical products developer Ascletis Pharma Inc 1672.HK jump 8.7% to HK$7.99, their highest since March 2019
** Stock on course for the biggest one-day gain since March 3; on track for third straight session of rise
** Ascletis announces positive topline results of Phase 1B studies of weight loss drug candidate ASC47 monotherapy in Australia
** Says U.S. Food and Drug Administration has cleared the U.S. Investigational New Drug application for ASC47 in combination with semaglutide for the treatment of obesity
** Hong Kong's healthcare index .HSCIH and Hang Seng Index .HSI both slip 0.1%
** Stock up 144.2% YTD
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。